Most Popular
-
1
Yoon’s jailed mother-in-law excluded from latest parole list
-
2
[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
3
Korea’s homegrown nanosatellite successfully launches into space
-
4
Nicaragua shuts down Seoul embassy
-
5
Rocket engine expert, ex-NASA exec to lead Korea's new space agency
![[Herald Interview] 'Amid aging population, Korea to invite more young professionals from overseas'](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/24/20240424050844_0.jpg&u=20240424200058)
-
6
SNU profs to suspend treatment for one day
-
7
SK hynix pledges W20tr to ramp up DRAM production at home
-
8
Hybe's multilabel system tested amid conflict with Ador
-
9
Over-50s, men, single-person households take up majority of those filing for bankruptcy
-
10
Aging population to drive down Korea's housing prices from 2040: experts
[THE INVESTOR] Korean pharma company BioLeaders will list on the secondary bourse KOSDAQ on July 7.
Established in 1999, the company develops drugs for immune disorders and other incurable diseases.
Established in 1999, the company develops drugs for immune disorders and other incurable diseases.
Prior to listing on the tech-heavy KOSDAQ, BioLeaders was traded on KONEX -- a securities exchange exlusively for small and medium enterprises and venture companies.
It will issue 1.2 million shares within the range of 11,000 won (US$9.5) to 15,000 won per share. The company expects to raise 13.2 billion won to 18 billion won.
By Ahn Sung-mi (sahn@heraldcorp.com)
